Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2025 12:05 ET | Source: Bragar Eagel & Squire

UNICYCIVE ALERT: Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Defendants allegedly overstated Unicycive’s FDA readiness for its OLC NDA; later cGMP issues at a subcontractor led to FDA setbacks and stock drops.
October 13, 2025 15:41 ET | Source: Portnoy Law

Portnoy Law Firm Announces Class Action on Behalf of Unicycive Therapeutics, Inc. Investors

LOS ANGELES, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Unicycive Therapeutics, Inc., (“Unicycive” or the "Company") (NASDAQ: UNCY) investors off a class action on behalf of...
October 13, 2025 11:41 ET | Source: Bragar Eagel & Squire

UNICYCIVE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors in Unicycive to Contact the Firm Before the October 14th Deadline in the Filed Class Action Lawsuit

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th...
October 12, 2025 14:17 ET | Source: The Rosen Law Firm PA

ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important October 14 Deadline in Securities Fraud Lawsuit – UNCY

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March...
October 12, 2025 08:52 ET | Source: Faruqi & Faruqi LLP

UNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you suffered...
October 10, 2025 13:57 ET | Source: Bragar Eagel & Squire

UNICYCIVE REMINDER: Bragar Eagel & Squire, P.C. Urges Investor to Contact the Firm Before the October 14th Deadline

Unicycive allegedly overstated its readiness to meet FDA manufacturing standards for its OLC drug NDA for treating hyperphosphatemia.
October 09, 2025 15:32 ET | Source: Portnoy Law

Portnoy Law Firm Announces Class Action on Behalf of Unicycive Therapeutics, Inc. Investors

LOS ANGELES, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Unicycive Therapeutics, Inc., (“Unicycive” or the "Company") (NASDAQ: UNCY) investors off a class action on behalf of...
October 08, 2025 10:45 ET | Source: Faruqi & Faruqi LLP

UNCY DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you suffered...
October 06, 2025 19:00 ET | Source: The Rosen Law Firm PA

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCY

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March...
October 06, 2025 14:02 ET | Source: Bragar Eagel & Squire

UNICYCIVE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the October 14th Deadline in the Unicycive Class Action Lawsuit

Unicycive allegedly overstated its readiness to meet FDA manufacturing standards for its OLC drug for kidney disease patients.